Related Experiment Videos
[Rilmenidine in rosacea: a double-blind study versus placebo]
E Grosshans1, C Michel, B Arcade
1Clinique Dermatologique des Hôpitaux Universitaires de Strasbourg.
Annales De Dermatologie Et De Venereologie
|January 1, 1997
Summary
Rilmenidine did not effectively treat rosacea papules and pustules. While it may reduce flushing, the study had limitations including a significant placebo effect and patient dropouts.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Current rosacea treatments like cyclines and metronidazole primarily target papules and pustules.
- Clonidine has been used for rosacea flushing, but rilmenidine offers more specific imidazoline receptor action without sedation.
Purpose of the Study:
- To evaluate the efficacy of rilmenidine 1 mg/d in treating rosacea.
Main Methods:
- A randomized, double-blind, placebo-controlled study involving 41 rosacea patients.
- Assessed treatment efficacy over 3 months, defining responders as those with >50% reduction in papules/pustules.
- Minor criteria included changes in flushing and facial redness.
Main Results:
- No significant difference in papule/pustule reduction or redness between rilmenidine and placebo groups.
- Rilmenidine showed a trend towards greater reduction in flushing (p=0.076) but was not statistically significant.
- Similar proportions of patients experienced minor side effects in both groups.
Conclusions:
- Rilmenidine is not effective for papulopustular rosacea but may offer some benefit for flushing.
- Study conclusions are limited by a high placebo effect and significant patient dropout.
- Further research with larger cohorts and vascular component focus is recommended.